Diagnosing Alzheimer’s Disease (AD) requires a thorough examination that includes an assessment of the patient's medical history, cognitive evaluations, a physical examination, and a neurologic examination.
Accurate diagnosis, prognosis, and disease monitoring are notoriously difficult when relying on clinical information only. Therefore, biomarkers reflecting the underlying pathologic mechanisms, such as amyloid-β deposition and phosphorylated tau (p-tau), play an important role; research has shown that they correlate with pathological features of the disease1.
Phosphorylated tau in threonine 181 (pTau-181) biomarker strongly corresponds to the density of amyloid- β plaques and tau tangles measured by PET scanning2,3.